FIELD: medicine.
SUBSTANCE: invention can be used to identify a high risk of developing impaired glucose tolerance in patients with stable effort angina with underlying administering beta-adrenergic blocking agents with no additional vasodilating properties. Therapy is preceded by conducting 2 exercise tests on the same day to achieve a threshold load power according to the same protocol, initially and 2 hours after administering a single dose of the beta-adrenergic blocking agents. If observing an interval gain of 120 seconds and more from the beginning of the load to the angina attack and/or reduction of an ischemic ST segment on the electrocardiogram not less than 1 mm at the 2nd load as compared to the 1st load, a risk of impaired glucose tolerance is considered to be high. A glucose tolerance test is carried out in these patients 4-5 weeks after the scheduled administration of the beta-adrenergic blocking agents. If impaired glucose tolerance is detected, administering the beta-adrenergic blocking agents is withdrawn. If the 2nd load as compared to the 1st load shows an interval to the angina attack and/or reduction of the ischemic ST segment on the electrocardiogram at a depth not less than 1 mm increasing less than by 120 seconds, a risk of developing impaired glucose tolerance is considered to be negligible. Treatment of these patients with the beta-adrenergic blocking agents is continued without the glucose tolerance test required.
EFFECT: method provides preventing carbohydrate metabolic disorders by the early identification of the high risk of developing impaired glucose tolerance in the given patients by detecting a compensatory increase of the glucose consumption with insulin resistance and a lower availability of free fatty acids to provide myocardial energy needs.
6 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR EARLY DETECTION OF HIGH RISK OF DEVELOPING IMPAIRED GLUCOSE TOLERANCE WITH UNDERLYING METOPROLOL ADMINISTRATION IN PATIENTS WITH STABLE EFFORT ANGINA | 2011 |
|
RU2498306C2 |
METHOD TO MATCH AN EFFECTIVE DOSAGE OF BETA-ADRENOBLOCKERS IN ISCHEMIC PATIENTS | 2000 |
|
RU2180796C1 |
METHOD FOR SETTING DILTIAZEM DOSE FOR TREATMENT OF PATIENTS WITH POST-INFARCT CARDIOSCLEROSIS AND CIRCULATION INSUFFICIENCY OF FUNCTIONAL CLASS 2 | 2003 |
|
RU2255740C2 |
METHOD FOR PREDICTING ISCHEMIC VENTRICULAR RHYTHM DISORDERS IN PATIENTS WITH ISCHEMIC CARDIAC DISEASE | 2004 |
|
RU2280402C2 |
METHOD FOR PREVENTING OSTEOPOROSIS IN PATIENTS WITH CICD | 2005 |
|
RU2294747C1 |
METHOD OF TREATING PATIENTS SUFFERING CHRONIC CARDIAC FAILURE COMPROMISED TYPE 2 DIABETES | 2010 |
|
RU2421218C1 |
METHOD FOR PREDICTING THE TOLERANCE TO NITRATES | 1999 |
|
RU2196501C2 |
METHOD OF TREATING CARDIOVASCULAR PATIENTS AFTER SUFFERING ACUTE CORONARY SYNDROME AND CARDIOSURGICAL INTERVENTIONS | 2019 |
|
RU2715209C1 |
METHOD FOR OBTAINING QUANTITATIVE INDIVIDUAL ANTIANGINAL PREPARATION EFFICIENCY EVALUATION BY MEANS OF MYOCARDIAL LOADING SCINTIGRAPHY WITH TALLIUM-199 IN PATIENTS SUFFERING FROM MYOCARDIAL ISCHEMIA WITH STABLE ANGINA PECTORIS | 2000 |
|
RU2190960C2 |
METHOD OF DIAGNOSING GESTATIONAL DIABETES MELLITUS | 2013 |
|
RU2557978C2 |
Authors
Dates
2014-07-20—Published
2012-12-04—Filed